Life Sciences

  • March 24, 2026

    FTC To Mull Caremark Deal In PBM Insulin Pricing Case

    Federal Trade Commission staffers have asked to let the agency's commissioners consider a potential settlement with Caremark in a case accusing pharmacy benefit managers of inflating insulin prices through rebate schemes, following a recent deal with Express Scripts.

  • March 24, 2026

    Beasley Allen Says NJ Justices Review Of Talc DQ 'Essential'

    Beasley Allen urged the New Jersey Supreme Court to hear its appeal of a lower court's decision to disqualify it from representing plaintiffs in multicounty litigation over Johnson & Johnson's talc-based baby powder, arguing that the court's immediate review of the interlocutory order is "essential."

  • March 24, 2026

    Ohio Justices Likely Split On Trans Care Restrictions

    The Ohio Supreme Court appeared split Tuesday as to whether a new state law banning gender-affirming care for minors trumps a decade-old healthcare freedom provision passed by voters that says state laws can't block a patient from obtaining healthcare. 

  • March 24, 2026

    Fired Ipsen Director Accuses The Pharmaceutical Co. Of Bias

    A researcher and pharmaceutical executive brought in to help "right the ship" at an Ipsen Pharmaceuticals subsidiary says after a change in management, she was subjected to gender, age and racial bias and then fired.

  • March 24, 2026

    Justices Won't Review Class Cert. In Diabetes Drug Risk Case

    The U.S. Supreme Court has declined to review whether a federal court can certify a class of third-party payors who claim drugmakers hid the cancer risks of an anti-diabetes drug.

  • March 23, 2026

    CooperSurgical Fights Docs Request In Embryo Loss Suit

    Fertility company CooperSurgical Inc. is pushing back against a bid to compel the release of internal financial and other records in litigation brought by a couple who claims the company negligently destroyed their embryos with its recalled culture media, calling the request overly broad.

  • March 23, 2026

    Amarin Tells Justices Hikma Drug Patent Appeal Threatens IP

    Amarin Pharma Inc. has urged the U.S. Supreme Court to uphold a decision that it plausibly alleged that generics maker Hikma Pharmaceuticals USA Inc. encouraged infringement of patents on the heart drug Vascepa, saying a reversal "would dramatically dilute intellectual property protection throughout the nation."

  • March 23, 2026

    Revance Investors Ink $17M Deal In Take-Private Offer Suit

    Dermal fillers company Revance Therapeutics Inc. and two of its executives have agreed to a $17 million settlement to end claims the company hurt investors after the value of a take-private tender offer was negotiated down following allegations that Revance had breached a distribution deal with another company.

  • March 23, 2026

    J&J Amici Seek Clarity On Goldman Precedent For Class Cert.

    Four groups of amici have urged the U.S. Supreme Court to take up Johnson & Johnson's challenge to a Third Circuit decision allowing a securities class action over its talc products to proceed, warning the ruling could reshape how shareholder suits are litigated nationwide.

  • March 23, 2026

    Stem Cell Clinic Accused Of Deceiving Patients

    An operator of clinics offering stem cell and plasma therapies lures in desperate patients for unproven treatments marketed as guaranteed cures with no-interest payments, according to a proposed class suit filed Monday in Miami.

  • March 23, 2026

    Med Mal Claims Proceed In Fertility Clinic Wrong Sex Suit

    A New York federal judge will let medical malpractice and fraud claims proceed in a suit from a couple alleging they had a male child after a fertility clinic's staff guaranteed they would have a girl, while dismissing breach of contract and other claims.

  • March 23, 2026

    Novartis Faces Class Suit Over Patient Health Info Disclosure

    Drugmaker Novartis collected patients' personal and health information through pharmaceutical marketing websites and transmitted it to third parties including Google using "surreptitious online tracking tools" without patients' consent, a proposed class action in New Jersey federal court alleges.

  • March 23, 2026

    Agilent, Axion End Cell Analysis IP Suit After Jury Selection

    Laboratory equipment company Agilent Technologies and biotechnology business Axion BioSystems have agreed to end litigation accusing Axion of patent infringement, just before trial was to start Monday.

  • March 23, 2026

    Federal Prosecutors Fight Bail Bid For Convicted Biotech CEO

    Federal prosecutors are fighting former CytoDyn CEO Nader Pourhassan's bid to stay free on bail while he appeals his securities fraud and insider trading convictions, arguing in Maryland federal court that the executive's arguments on appeal are little more than recycled versions of the failed claims he made in seeking a new trial.

  • March 23, 2026

    Feds Approve Minnesota's Plan To Combat Medicaid Fraud

    Minnesota may soon receive the release of $243 million in deferred Medicaid funds after the Centers for Medicare & Medicaid Services approved the state's updated plan to combat Medicaid fraud, Minnesota state health officials told a federal court last week.

  • March 23, 2026

    AbbVie Escapes Ill. Genetic Privacy Lawsuit

    An Illinois federal judge on Friday granted AbbVie summary judgment in a lawsuit claiming it violated the state's genetic privacy law, saying there was "no genuine dispute" that AbbVie never conditioned the plaintiff's employment on whether he disclosed genetic information in the physical exam he was required to undergo before starting work.

  • March 23, 2026

    High Court Won't Hear Mich. Newborn Blood Testing Case

    The U.S. Supreme Court on Monday declined to hear a petition from parents seeking to revive claims that the way newborn blood samples are collected and stored in a Michigan health screening program violates their rights to make medical decisions for their children.

  • March 23, 2026

    Fecal Treatment Co. Files Ch. 11 To Escape Lease, Sell IP

    A company that develops treatments to improve the health of the body's microbiome sought Chapter 11 protection, saying it had never generated a positive cash flow and faces unresolved litigation and a burdensome lease.

  • March 23, 2026

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court's docket this past week featured high-stakes disputes involving major consumer brands, a reinstated video game executive, revived noncompete and compensation claims and fresh allegations of corporate misconduct in the healthcare sector.

  • March 23, 2026

    Justices Won't Review Lab Owner's Kickback Conviction

    The U.S. Supreme Court on Monday declined to review the conviction of a former California biotech president sentenced to eight years in prison for lying about the efficacy of his company's COVID-19 and allergy testing and conducting a $70 million Medicare fraud scheme. 

  • March 23, 2026

    Justices Pass On Challenge To Courts' Sanctions Authority

    The U.S. Supreme Court on Monday declined a dietary supplement company's request to review sanctions it was issued at trial in a false advertising dispute, in a case that could have led justices to clarify when courts may use their inherent authority to sanction parties for litigation conduct.

  • March 20, 2026

    Feds Rip Ex-NFL Player's New Trial Bid Over Medicare Scheme

    The federal government opposed a new trial bid by Keith Gray, a former NFL player and Texas laboratory owner convicted in a $328 million scheme involving billing for unnecessary cardiovascular genetic testing for Medicare beneficiaries, arguing Thursday he lacks any valid basis to "disturb the jury's sound verdict."

  • March 20, 2026

    Former Gilead Sciences GC To Earn Over $2.5M Severance

    Gilead Sciences Inc. is paying its former general counsel more than $2.5 million in severance after she left the company, according to a U.S. Securities and Exchange Commission filing released Friday.

  • March 20, 2026

    CytoDyn Settles Investor Suit With $500K, 49M Shares

    Biotechnology firm CytoDyn has agreed to dole out 49 million shares of common stock and pay $500,000 to end investors' proposed class action accusing the company of overstating the likelihood that the U.S. Food and Drug Administration would approve a drug it claimed could treat HIV and COVID-19.

  • March 20, 2026

    Feds To Cover Ayahuasca Church's Legal Fees, 9th Circ. Says

    The federal government is on the hook for more than $2 million in attorney fees following a settlement with a Phoenix-based church over its right to use the psychedelic beverage ayahuasca in religious ceremonies, a divided Ninth Circuit panel said in an unpublished opinion Friday.

Expert Analysis

  • Series

    Traveling Solo Makes Me A Better Lawyer

    Author Photo

    Traveling by myself has taught me to assess risk, understand tone and stay calm in high-pressure situations, which are not only useful life skills, but the foundation of how I support my clients, says Lacey Gutierrez at Group Five Legal.

  • Latest PTAB Moves Suggest A Subtle Recalibration

    Author Photo

    Recent decisions from the Patent Trial and Appeal Board, as U.S. Patent and Trademark Office Director John Squires transitions into his new role, offer new procedural and substantive tools for patent owners in procuring patent rights and enforcing them against would-be petitioners, say attorneys at Morgan Lewis.

  • Opinion

    DOJ's Tracing Rule For Pandemic Loan Fraud Is Untenable

    Author Photo

    In conducting investigations related to COVID-19 relief fraud, the government's assertion that loan proceeds are nonfungible and had to have been segregated from other funds is unsupported by underlying legislation, precedent or the language establishing similar federal relief programs, say Sharon McCarthy, Jay Nanavati and Lasya Ravulapati at Kostelanetz.

  • Del. Ruling Reaffirms High Bar To Plead Minority Control

    Author Photo

    The Delaware Court of Chancery's recent decision in Witmer v. Armistice maintains Delaware's strict approach to control and provides increased predictability for minority investors in their investment and corporate governance decisions, says Elena Davis at Ropes & Gray.

  • Series

    Law School's Missed Lessons: Client Service

    Author Photo

    Law school teaches you how to interpret the law, but it doesn't teach you some of the key ways to keeping clients satisfied, lessons that I've learned in the most unexpected of places: a book on how to be a butler, says Gregory Ramos at Armstrong Teasdale.

  • How Occasional Activists Have Reshaped Proxy Fights

    Author Photo

    The sophistication and breadth of first-time activist engagement continue to shape corporate governance and strategic outcomes, as evidenced across corporate annual meetings this summer, meaning advisers should anticipate continued innovation in tactics, increased regulatory complexity, and a persistent focus on board accountability, say attorneys at MoFo.

  • What To Expect After FDA Warnings To GLP-1 Compounders

    Author Photo

    The U.S. Food and Drug Administration's recent warning letters to companies advertising compounded versions of GLP-1 medications raise questions not just about the enforcement outlook for marketing such products, but also about the future of drug compounding as a whole, say attorneys at Spencer Fane.

  • Where 4th And 9th Circ. Diverge On Trade Secret Timing

    Author Photo

    Recent Fourth and Ninth Circuit decisions have revealed a deepening circuit split over when plaintiffs must specifically define their alleged trade secrets, turning the early stages of trade secret litigation into a key battleground and elevating the importance of forum selection, say attorneys at Skadden.

  • Series

    Adapting To Private Practice: 3 Tips On Finding The Right Job

    Author Photo

    After 23 years as a state and federal prosecutor, when I contemplated moving to a law firm, practicing solo or going in-house, I found there's a critical first step — deep self-reflection on what you truly want to do and where your strengths lie, says Rachael Jones at McKool Smith.

  • Series

    Painting Makes Me A Better Lawyer

    Author Photo

    Painting trains me to see both the fine detail and the whole composition at once, enabling me to identify friction points while keeping sight of a client's bigger vision, but the most significant lesson I've brought to my legal work has been the value of originality, says Jana Gouchev at Gouchev Law.

  • Courts Are Still Grappling With McDonnell, 9 Years Later

    Author Photo

    The Seventh and D.C. Circuits’ recent decisions in U.S. v. Weiss and U.S. v. Paitsel, respectively, demonstrate that courts are still struggling to apply the U.S. Supreme Court’s 2016 ruling in McDonnell v. U.S., which narrowed the scope of “official acts” in federal bribery cases, say attorneys at Quinn Emanuel.

  • AI Will Transform Patent Examination For The Better

    Author Photo

    The U.S. Patent and Trademark Office's increasing use of artificial intelligence tools will result in patents that are more thoroughly vetted, and patent applicants and practitioners will need to adapt their drafting strategies and address stronger and more sophisticated rejections, say attorneys at Troutman.

  • Hybrid Claims In Antitrust Disputes Spark Coverage Battles

    Author Photo

    Antitrust litigation increasingly includes claims for breach of warranty, product liability or state consumer protection violations, complicating insurers' reliance on exclusions as courts analyze whether these are antitrust claims in disguise, says Jameson Pasek at Caldwell Law.

  • Drug Ad Crackdown Demonstrates Admin's Aggressive Stance

    Author Photo

    Recent actions by the U.S. Food and Drug Administration and U.S. Department of Health and Human Services targeting pharmaceutical companies' allegedly deceptive advertising practices signal an active — potentially even punitive — intent to regulate direct-to-consumer advertising out of existence, say attorneys at King & Spalding.

  • Protecting Sensitive Court Filings After Recent Cyber Breach

    Author Photo

    In the wake of a recent cyberattack on federal courts' Case Management/Electronic Case Files system, civil litigants should consider seeking enhanced protections for sensitive materials filed under seal to mitigate the risk of unauthorized exposure, say attorneys at Redgrave.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.